Cas:175135-15-6 2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole manufacturer & supplier

Chemical Name:2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole

CAS.NO:175135-15-6

Synonyms:3-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)propan-1-ol;3-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]propan-1-ol;3-[5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl]propan-1-ol;MFCD00067735

Molecular Formula:C₁₁H₁₁F₃N₂O

Molecular Weight:244.21300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:139-141ºC

Boiling point:431.9ºC at 760 mmHg

Density:1.392g/cm3

Index of Refraction:1.567

PSA:48.91000

Exact Mass:244.08200

LogP:2.50660

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)propan-1-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00067735 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00067735 Use and application,3-[5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl]propan-1-ol technical grade,usp/ep/jp grade.

Related News: China is now dealing with another disease outbreak �� this one mostly affecting animals but also potentially deadly among people. 2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole supplier Alira is betting big on biometrics services by picking up Italy-based CROS NT, which has offices in Italy, London and North Carolina. The deal, for undisclosed terms, gives a boost to Alira’s direct clinical operations in Europe and access to biometrics services from the 29-year-old contract research organization. 2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole vendor Alira is betting big on biometrics services by picking up Italy-based CROS NT, which has offices in Italy, London and North Carolina. The deal, for undisclosed terms, gives a boost to Alira’s direct clinical operations in Europe and access to biometrics services from the 29-year-old contract research organization. 2-(3-Hydroxy-n-propyl)-5-(trifluoromethyl)-benzimidazole factory Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.